Effect of pirenzepine, a new gastric acid-inhibiting agent, on exocrine pancreatic secretion in man.
The effect of orally ingested 5,1-dihydroxy-11- (4-methyl-1-piperazinyl)-acetyl-6H-pyrido(2,3-b)-I, 4-benzodiazepin-6-one dihydrochloride (LS 519, pirenzepine), a newly developed compound with gastric secretion-inhibitory action but without central-nervous sedation, on the secretion of fluid into the duodenum and on pancreatic enzyme output was studied by a marker perfusion technique in 10 human subjects. A short-lasting increase in duodenal volume was observed, while output of trypsin and lipase remained unchanged. Central and autonomic nervous actions seem unlikely, a possible release of endogenous secretion was discussed.tin was discussed.